Company intelligence / Profile preview

Cellastra Inc.

San Francisco, California, United Statescellastra.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Cellastra has developed proprietary gene therapy assets targeting scar prevention and tissue repair. Their lead programs use AAV6-based vectors to induce local production of natural anti-scarring peptides. Early clinical studies have shown safety and efficacy for their approach in wound healing contexts. The company recently received a US patent for recombinant gene vectors encoding human lactoferrin proteins for scar/adhesion prevention. No late-stage or pivotal trial results are reported as of May 2025[1][4].

Therapeutic areas: PulmonologyDermatologyInfectious Diseases
Modalities: Gene therapy (AAV6 vector)Recombinant viral vectorsPeptide therapeutics (e.g., lactoferrin, ensereptide)
Industry: Biotech

Drug pipeline

2 assets

Scarlexa

Pre-clinical

Indications: Post-surgical scarring, Burn injuries

1 more asset in the full pipeline.

Request access →

Partnerships

Centre for Advances Medical Products (CAMP), Sweden – collaboration on burn injury treatments using Cellexa technology [2]Partnerships with world-class institutions for preclinical/clinical development are mentioned but not individually named [2].

Beyond the preview

Go deeper on Cellastra Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellastra Inc..

Explore the full profile